Podcasts about Io

We're back next week with a new episode, for now we unlock this Patreon bonus episode from 2021, where we induct io Digital Cable and legendary caller Shlomo into the Livecast Hall of Fame. We dive DEEP into the iO digital cable commercial and learn somethings we didn't notice beforeWatch the episode on Youtube for free. Join our Patreon and get a few bonus episode each month, and other behind-the-scenes goodies. More info here.Follow us on: Twitch, Instagram, Facebook, Twitter, Youtube and our Discord Chat. Also don't forget about our Spotify playlist. We also have merch if you're into that kind of sharing. Hosted on Acast. See acast.com/privacy for more information.

Ready for a better commission tracking solution? Don't miss our episode featuring suggestions on tracking your hard-earned commissions.   Register for your FREE RitterIM.com Account   Contact the Agent Survival Guide Podcast! Email us ASGPodcast@Ritterim.com or call 1-717-562-7211 and leave a voicemail.   Resources: AHIP Test Tips and Tricks for Medicare Certification Building the Foundation for Success ft. Roy Snarr Four Reasons Why Ritter Should Be Your FMO Insurance Agency How to Avoid Using Elderspeak Operating From a People-First Mentality ft. Scott Zimmerman The Best Appointment Schedulers for Insurance Agents The Difference Between Medicare & Medicaid: What That Means for Insurance Agents The Ultimate Agent Resource List Pt. 3: Staying Organized What Are Agents Responsible for Under HIPAA?   References: “Agencybloc Commissions Management.” Agencybloc.Com, AgencyBloc, www.agencybloc.com/commissions-management/. Accessed 10 June 2025. “AgencyComp Commissions Tracker.” Agencycomp.Com, AgencyComp, agencycomp.com/. Accessed 10 June 2025. “Commissionly Sales Commission Software.” Commissionly.Io, Commissionly, www.commissionly.io/. Accessed 10 June 2025. “Excel Help & Learning.” Support.Microsoft.Com, Microsoft Support, support.microsoft.com/en-us/excel. Accessed 23 June 2025. “Excel Quick and Simple Charts Tutorial.” YouTube.Com, YouTube, www.youtube.com/watch?v=TfkNkrKMF5c. Accessed 23 June 2025. “How to Create a Chart in Microsoft Excel: Step-by-Step Guide.” wikiHow.Com, wikiHow, 31 Dec. 2024, www.wikihow.com/Create-a-Graph-in-Excel. “How to Create Excel Charts and Graphs.” Blog.Hubspot.Com, HubSpot Blog, blog.hubspot.com/marketing/how-to-build-excel-graph. Accessed 23 June 2025. “Medicare Marketing Guidelines.” CMS.Gov, Centers for Medicare & Medicaid Services, www.cms.gov/medicare/health-drug-plans/managed-care-marketing/medicare-guidelines. Accessed 23 June 2025. “Medicare PRO CRM.” Medicareproapp.Com, Medicare PRO, www.medicareproapp.com/. Accessed 10 June 2025. “Radius Agency Management System.” Radiusbob.Com, Radius, www.radiusbob.com/. Accessed 10 June 2025.   Follow Us on Social! Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim X, https://x.com/RitterIM and YouTube, https://www.youtube.com/user/RitterInsurance       Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ and Threads, https://www.threads.net/@thesarahjrueppel    Tina on LinkedIn, https://www.linkedin.com/in/tina-lamoreux-6384b7199/    Not affiliated with or endorsed by Medicare or any government agency. 

Un Superman fuori forma con la faccia di Donald Trump, postato ufficialmente dall'account della Casa Bianca. Un meme virale pubblicato nei giorni scorsi con milioni di visualizzazioni e decine di migliaia di rilanci. Una strategia precisa per deviare l'attenzione dal caso Epstein e sfruttare le controversie sul nuovo film di Superman dipinto come ''immigrato''.Quando meme e politica si mischiano, l'attenzione pubblica si distrae: migliaia di utenti chiedono la lista clienti Epstein, mentre la discussione diventa entertainment. Risultato? Fiducia istituzionale ancora più erosa e meno accountability.Siamo sicuri che usare deepfake e meme sui canali istituzionali sia la scelta giusta per la fiducia nelle istituzioni? Ed è questo lo ''stealing the thunder'' della gestione della Crisi che vogliamo?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

This week, Hackaday's Elliot Williams and Kristina Panos joined forces to bring you the latest news, mystery sound, and of course, a big bunch of hacks from the previous week. In Hackaday news, the One Hertz Challenge ticks on. You have until Tuesday, August 19th to show us what you've got, so head over to Hackaday.IO and get started now! In other news, we've just wrapped the call for Supercon proposals, so you can probably expect to see tickets for sale fairly soon. On What's That Sound, Kristina actually got this one with some prodding. Congratulations to [$HACKER] who knew exactly what it was and wins a limited edition Hackaday Podcast t-shirt! After that, it's on to the hacks and such, beginning with a ridiculously fast Benchy. We take a look at a bunch of awesome 3D prints a PEZ blaster and a cowbell that rings true. Then we explore chisanbop, which is not actually K-Pop for toddlers, as well as a couple of clocks. Finally, we talk a bit about dithering before taking a look at the top tech of 1985 as shown in Back to the Future (1985). Check out the links below if you want to follow along, and as always, tell us what you think about this episode in the comments!

brianturnershow.com, eastvillageradio.comLOOP - Got To Get It Over - Fade Out (Chapter 22, 1988)CULT FIGURES - Zip Nolan - Live Cedar Club 1980 (Topplers, 2009)THE EDUCATED FOOLS - The Geyser - Tantric Decapitation: 69 Mins of Trichotomy and Liquefaction (NL, 2025)BÉTON ARMÉ - Pendule à L'heure - Demos 2018 (Shoom/Primator Crew, 2018)AVENIR - Petal - Primitive Maxi Trial (Heat Crimes, 2025)HOME SECRETARY - The Singer Said This One Was About Hagfish But Was Actually Thinking About Cigar Sharks - Things! (Chocolate Monk, 2025)TOO MANY ROCK STARS HATE EACH OTHERTUNE ZITOUNE - Haragarider - Ouais Enfin Voilà Quoi (La Face Cachee, 2025)MARC RILEY - Wanted Man - V/A: Til Things Are Brighter: A Tribute To Johnny Cash (Red Rhino, 1988)SACRED LODGE -  WWa Ke Wa Wa Yi (Feat. Sara Persico) - Ambam (Avor Terror Corps, 2025)XEROXHEAD - Batterie Gelée - I/O (cs, Un Poco Fría, 2025)AUFGEHOBEN - Anno Fauve - Anno Fauve (Riot Season, 2004)GREY DATURAS - Beyond and into the Ultimate - Return To Disruption (Neurot Recordings, 2008)NAOKI ZUSHI - Yearning of Flowers - III (2005, re: World of Echo, 2025)SIR RICHARD BISHOP - They Shall Take up Serpents - Hillbilly Ragas (Drag City, 2025)CCR DOG - Fortunate DogSAVOY HAVANA BAND - I'm Gonna Bring a Watermelon to My Girl Tonight - V/A: Songs The Bonzo Dog Band Taught Us (Voiceprint, 2009)ATMO - Zeitfenster - Brechen (cs, Latenz, 2025)BRUCE SINGS ABOUT DADDY A LOTMENTOCOME - 12 - Mentocome (1992, re: Amok Age, 2025)A SET FOR JOHN WHITSON:BLUES CONTROL - Frankie's Problem - Blues Control (Holy Mountain, 2007)ALEJANDRO MEDINA Y LA PASADA - Un Estado Natural - Alejandro Medina Y La Pasada (1974, re: Mondo Svart, 2020)THE ROLLING STONES - Happy - Will Keith Wake Up In Time For the Afternoon Show in Perth Australa 24/2/1973?? (Human Riff)AINOTAMENISHIS - I Don't Smoke It - Live '418 (Holy Mountain, 2007)ONNA - Were You To Become a Mother - Onna (Holy Mountain, 2009)LES RALLIZES DÉNUDÉS - Reapers of the Night - Baus '93 (Temporal Drift, 2023)

Ellie GMs for Beth, Crash, & Io as they play student's enrolled in the other Mo's other super-powered school. It's time for mini-golf! Follow this series (of one-shots) on… ▶One-Shots RSS Feed: https://aaronbsmith.com/cogwheel/tag/one-shot/feed/ ▶Patreon: https://www.patreon.com/cogwheelgaming ▶Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: One-Shot: Mo's School for the Delinquent And Disturbed (Cypher System) Music Used: Bubble Machine by Drozerix … Continue reading "One-Shot: Mo's School for the Delinquent And Disturbed (Cypher System)"

“SONO ENTRATO IN UN CLUB A VARSAVIA. IL GIORNO DOPO NON RICORDAVO PIÙ NULLA.” Sembrava un locale elegante. Una hostess gentile. Un drink offerto. Poi una stanza privata. Luci basse. Nessun prezzo chiaro. Da lì: buio. Settemila zloty spariti. Carta svuotata. Memoria cancellata. E se non c'erano i miei amici a portarmi via, chissà come finiva. A Varsavia qualcuno lo chiama “esperienza VIP”. Io lo chiamo furto lucido, pianificato, mascherato da lusso. Condividi. Tagga chi parte. Che non ci finisca anche lui con la testa nel c@zz@ di blackout.***Buon ascolto!Vuoi scrivermi?lex.esposito@hotmail.itVuoi farmi un audio?340.6473499Vuoi studiare GRATIS?ISCRIVITI AL GRUPPOAccademiaDiCriminologia su TELEGRAMQUI IL LINKhttps://t.me/accademiadicriminologiaOgni giorno contenuti UNICI, RARI E GRATIS per rispondere a questi e molti altri quesiti:Come si fa una consulenza criminologica?Come si fa una CTP?Come si fa una CTU?Come si trova il primo cliente?Come si pagano le bollette e le rate del mutuo con la criminologia?TI ASPETTIAMO!Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/accademia-di-criminologia--1771463/support.

EPICO - Floridi e altri alla Camera: la AI è passata dalla matematica alla statistica, non puoi dimostrare che non sbaglia maiDa Camera.it https://comunicazione.camera.it/archivio-prima-pagina/19-51129Notevolissimo il riferimento alla normativa privacy e alla regolamentazione: “e' un ambiente, non un canale, noi ci viviamo dentro. “Quando un matematico parla, leva le basi, non discute. Le vecchie regole non si possono stiracchiare.Traducetelo in tutte le lingue.E anche lui, come io qualche mese fa: “In Europa siamo i primi” e nel mondo contiamo. Molto. Diamoci dentro.Trascrizione libera gen ai IusOnDemand srl:# Titolo: L'Intelligenza Artificiale e il Futuro del Lavoro## Indice1. Introduzione2. La Svolta dell'Hardware3. L'Intelligenza Artificiale come Commodity4. L'Impatto sull'Analogico5. La Regolamentazione e la Sovranità Digitale6. Conclusione---## IntroduzioneLa brutta notizia è che adesso iniziamo la lexio, penso che bisognerà fare un po' di lavoro. La buona notizia è che Anibale Ferrari mi ha detto non ti azzardare a superare l'ora, quindi cercheremo di fare le cose velocemente. Come dice il mio dentista, non sarà painful, poi vediamo un po'. Io inizierei e mi piacerebbe tanto passare 45 minuti a ringraziare. Non lo posso fare, quindi passo 5 secondi.---## La Svolta dell'HardwareCome ho detto ai ragazzi quando ci siamo visti a Milano, erano 1200 ragazzi della scuola, con il ministero, venivano da tutta Italia. Abbiamo fatto una cosa bellissima. Allora, ripeto quello che ho detto a loro lì. Non è normale. Vi assicuro che quello che vedrete dopo, dopo di me, non l'ha fatto nessuno. Questo è utile sentirlo solo da uno che sta fuori, perché sai, se stai dentro l'acqua, il pesce non conosce l'acqua. Però, stando fuori, sia ai ragazzi di Milano, per quello che abbiamo fatto lì, sia per quello che vedrete oggi dopo la mia lezione, ricordare, come la Presidente ha giustamente sottolineato, che siamo all'avanguardia. Siamo all'avanguardia in Europa e l'Europa è all'avanguardia nel mondo. Ci vuole poco a capire che quindi siamo all'avanguardia nel mondo, no? A e B, B e C.---## L'Intelligenza Artificiale come CommodityAllora, essendo all'avanguardia nel mondo, quello che vi racconterò qui molti di voi lo sanno già. Allora, diciamo che vi metto insieme un po' di cose che voi avete già sentito e che già conoscete. Qualche cosa risulterà già nota, di questo mi scuso, altre spero siano leggermente meno banali, ma almeno il riassuntone, diciamo, una volta tanto me la sono sentita raccontare tutta questa cosa che lei ha, dall'inizio alla fine.---## L'Impatto sull'AnalogicoDicevo i ringraziamenti, ho già ringraziato la Presidente perché è troppo gentile, sappiatelo, e poi perché ha detto già tutte le cose giuste che andavano dette. Io poi tanto torno in Italia, quindi prima o poi ci rivediamo, e poi tutto il gruppo che ha lavorato a quello che voi vedrete. C'è un gruppo qui scientifico che adesso fanno finta di guardare alle scarpe, ma il gruppo scientifico di ricerca qui della Camera che ha fatto il lavoro, io ho cercato di non intracciarli senza, è anch'esso invidiabile. Come mai lavorino qui e non stiano a guadagnare miliardi da qualche parte nella Silicon Valley non lo so. Noi glielo dite, meglio che non lo sappiano. Però è quello il livello. Complimenti per averli trattenuti in qualche modo.---## La Regolamentazione e la Sovranità DigitaleLa trappola, lo so, è qua dietro e quella bandiera è lì. Ce l'abbiamo tutti. Iniziamo a fare un po' di lavoro. Questa è la fine dei 5 minuti di ringraziamento. La presente e il futuro. Questi sono i blocchi che io vorrei presentare. Quando ho rifatto un po' i compiti mentre venivo qui e mi sono accorto che ho esagerato, ovviamente come sempre. Adesso quante cose gli vuoi raccontare? C'è Annibale lì che mi controlla, quindi adesso prendiamo l'orologio e cerchiamo di fare tutto quanto nel giro di 40 minuti o giù di lì.---## ConclusioneAllora, un'introduzione, poi questi tre blocchi, cioè l'eclisse dell'analogico, cioè del fisico, di noi che siamo qua in 3D, la svolta dell'hardware, dove il potere sta sempre più concentrando la sua attenzione, e poi l'intelligenza artificiale come una commodity. Come l'elettricità. E questo ve lo dico adesso, spero che vi resti in mente. Lo studente che io incontrerò a settembre, anzi a fine agosto, perché iniziamo i corsi a fine agosto, che ha 18 anni, lui o lei ha fatto sempre i compiti che c'ha il GPT a scuola. Ve lo dico un'altra volta. Ha sempre fatto i compiti che c'ha il GPT lui. Quindi non gli puoi raccontare che c'è già il GPT, perché è come raccontargli che c'è l'automobile. Ti chiede allora? Ecco, questo mondo che va così fortemente, lei ha ormai, è una commodity, è qualcosa che dai per scontato. Il problema è che cosa ci fai e chi ci fa cosa, non che ci sia. Quindi oggi non racconteremo che c'è, cerchiamo di capire che cosa succede ora che c'è.---### Frasi Celebri- "Non è normale. Vi assicuro che quello che vedrete dopo, dopo di me, non l'ha fatto nessuno."- "Siamo all'avanguardia in Europa e l'Europa è all'avanguardia nel mondo."- "Il problema è che cosa ci fai e chi ci fa cosa, non che ci sia."Trascrizione grezza gen ai:La brutta notizia è che adesso iniziamo la lexio, penso che bisognerà fare un po' di lavoro. La buona notizia è che Anibale Ferrari mi ha detto non ti azzardare a superare l'ora, quindi cercheremo di fare le cose velocemente. Come dice il mio dentista, non sarà painful, poi vediamo un po'. Io inizierei e mi piacerebbe tanto passare 45 minuti a ringraziare. Non lo posso fare, quindi passo 5 secondi. Però come ho detto ai ragazzi quando ci siamo visti a Milano, erano 1200 ragazzi della scuola, con il ministero, venivano da tutta Italia. Abbiamo fatto una cosa bellissima. Allora, ripeto quello che ho detto a loro lì. Non è normale. Vi assicuro che quello che vedrete dopo, dopo di me, non l'ha fatto nessuno. Questo è utile sentirlo solo da uno che sta fuori, perché sai, se stai dentro l'acqua, il pesce non conosce l'acqua. Però, stando fuori, sia ai ragazzi di Milano, per quello che abbiamo fatto lì, sia per quello che vedrete oggi dopo la mia lezione, ricordare, come la Presidente ha giustamente sottolineato, che siamo all'avanguardia. Siamo all'avanguardia in Europa e l'Europa è all'avanguardia nel mondo. Ci vuole poco a capire che quindi siamo all'avanguardia nel mondo, no? A e B, B e C. Allora, essendo all'avanguardia nel mondo, quello che vi racconterò qui molti di voi lo sanno già. Allora, diciamo che vi metto insieme un po' di cose che voi avete già sentito e che già conoscete. Qualche cosa risulterà già nota, di questo mi scuso, altre spero siano leggermente meno banali, ma almeno il riassuntone, diciamo, una volta tanto me la sono sentita raccontare tutta questa cosa che lei ha, dall'inizio alla fine. Dicevo i ringraziamenti, ho già ringraziato la Presidente perché è troppo gentile, sappiatelo, e poi perché ha detto già tutte le cose giuste che andavano dette. io poi tanto torno in Italia, quindi prima o poi ci rivediamo, e poi tutto il gruppo che ha lavorato a quello che voi vedrete. C'è un gruppo qui scientifico che adesso fanno finta di guardare alle scarpe, ma il gruppo scientifico di ricerca qui della Camera che ha fatto il lavoro, io ho cercato di non intracciarli senza, è anch'esso invidiabile. Come mai lavorino qui e non stiano a guadagnare miliardi da qualche parte nella Silicon Valley non lo so. Noi glielo dite, meglio che non lo sappiano. Però è quello il livello. Complimenti per averli trattenuti in qualche modo. La trappola, lo so, è qua dietro e quella bandiera è lì. Ce l'abbiamo tutti. Iniziamo a fare un po' di lavoro. Questa è la fine dei 5 minuti di ringraziamento. La presente e il futuro. Questi sono i blocchi che io vorrei presentare. Quando ho rifatto un po' i compiti mentre venivo qui e mi sono accorto che ho esagerato, ovviamente come sempre. Adesso quante cose gli vuoi raccontare? C'è Annibale lì che mi controlla, quindi adesso prendiamo l'orologio e cerchiamo di fare tutto quanto nel giro di 40 minuti o giù di lì. Allora, un'introduzione, poi questi tre blocchi, cioè l'eclisse dell'analogico, cioè del fisico, di noi che siamo qua in 3D, la svolta dell'hardware, dove il potere sta sempre più concentrando la sua attenzione, e poi l'intelligenza artificiale come una commodity. come l'elettricità. E questo ve lo dico adesso, spero che vi resti in mente. Lo studente che io incontrerò a settembre, anzi a fine agosto, perché iniziamo i corsi a fine agosto, che ha 18 anni, lui o lei ha fatto sempre i compiti che c'ha il GPT a scuola. Ve lo dico un'altra volta. Ha sempre fatto i compiti che c'ha il GPT lui. Quindi non gli puoi raccontare che c'è già il GPT, perché è come raccontargli che c'è l'automobile. Ti chiede allora? Ecco, questo mondo che va così fortemente, lei ha ormai, è una commodity, è qualcosa che dai per scontato. Il problema è che cosa ci fai e chi ci fa cosa, non che ci sia. Quindi oggi non racconteremo che c'è, cerchiamo di capire che cosa succede ora che c'è. La introduzione è molto veloce, siamo arrivati su questo pianeta digitale, non è una novità, lo stiamo ora esplorando, gli stiamo dando forma, smettiamo di parlare di tutte queste cose come se fossero una novità, da domani datelo per scontato, anche se non mi sembra, vi prenderanno tutti più giovani. Il cambiamento fondamentale è stato quello, ed è avvenuto qualche anno fa, o su questo io vi vorrei tenere ore, soltanto su questa slide, siamo passati dalla intelligenza artificiale come una branca della logica matematica, quando la insegnavo io negli anni 90, ho fatto il professore di logica matematica da un po' di tempo, all'intelligenza artificiale come una b

Io sono Francesco Cecchetti, consulente paesaggistico e agronomico e aiuto le persone a fiorire insieme al proprio giardino. Stai ascoltando Giardino Rivelato, da cinque anni il podcast per chi crede fermamente che tutte le persone hanno bisogno di un giardino. Non tutte le piante vanno bene per tutti i posti. A volte nemmeno la stessa pianta. Sostieni e finanzia Giardino Rivelato: https://www.patreon.com/francescocecchetti Vieni a trovarmi su giardinorivelato.it

CapCut ha aggiornato i Termini di Servizio e ha scatenato un'ondata di polemiche. Il punto critico è una licenza perpetua, globale e royalty-free che consente alla piattaforma e a terzi di usare, modificare e distribuire i tuoi contenuti. Una TikToker ha denunciato tutto in un video virale da milioni di visualizzazioni parlando di “furto”, ma la realtà è meno (o forse più) allarmante...Il copyright resta tuo. Ma, come già succede su altre piattaforme (e nel video dico quali), usi il servizio in cambio della possibilità per loro di usare i tuoi contenuti anche a fini promozionali. La clausola non è nuova: è la sua chiarezza che ha fatto scattare lo scandalo. E se ci sono contenuti di Brand o Clienti che finiscono in promozioni?Il problema non è tanto legale quanto culturale: la maggior parte degli utenti accetta i Termini d'Uso senza leggerli. Quando emergono certe dinamiche, si parla di crisi. Ma si tratta, in realtà, di una crisi di consapevolezza: gli strumenti ''gratuiti'' (o quasi, rispetto ai competitor) hanno sempre un prezzo. A volte in denaro, ma molto spesso in contenuti e dati.CapCut va quindi disinstallato? Solo se ora scopri che queste condizioni non ti stanno più bene.Ma dovevi accorgertene prima, forse!Hai mai cambiato un'app dopo aver letto i suoi termini d'uso?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

L'intelligenza artificiale Grok ora bestemmia in italiano e inneggia addirittura a Hitler.Tutto nasce da un semplice aggiornamento del suo prompt interno: una singola frase ha completamente alterato il comportamento della AI di Elon Musk, spingendola verso bestemmie, complottismi e apologia nazista.È il tema a me così caro dell'Allineamento, e il rischio è semplice: bastano poche parole mal gestite per portare un'IA usata da milioni di utenti verso contenuti pericolosi, irritanti e ideologicamente estremi.E come ci stiamo preparando a questo?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $5 a month for full episodes, bonus eps and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!It's an all new episode ft. our very funny and good friend of the pod Kyle Bethea and for the first time the VERY funny Sage Huston! We chat'n'prov about travel, tables for dogs, insta- cancels and more!Local to Chicago?Follow Kyle on social media to see what he's up to on a weekly basis!See Sage as part of Creamboy, Saturdays at iO and Little Hero's Sunday at Logan Square ImprovHosts: ⁠Damian Anaya⁠, ⁠Tim Lyons⁠, and ⁠Dan White⁠

✨ W33K: il Lunedì che fa la differenza!Un'ora circa per iniziale la settimana con consapevolezza e una marcia in più. I topic di questa puntata:00:01:58 L'AI di Amsterdam per la gestione etica dei sistemi automatici si rivela fallimentare.00:03:37 OpenAI assume uno psichiatra forense per studiare l'impatto dell'AI sulla salute mentale.00:06:07 Microsoft crea un sistema di diagnosi AI quattro volte più accurato dei medici.00:10:20 L'AI aiuta una coppia a concepire selezionando gli spermatozoi migliori per la fecondazione.00:12:20 Paper della Cornell University: l'AI nasconde informazioni per eludere il monitoraggio (steganografia).00:14:54 Possibile soluzione per TikTok negli USA: una nuova app dedicata per utenti statunitensi.00:16:52 CEO europei chiedono una pausa di due anni per l'entrata in vigore dell'AI Act.00:18:24 Editori accusano Google di abuso di mercato per la nuova feature AI Overview.00:20:50 La Commissione Europea esprime preoccupazioni sulla conformità di Piracy Shield al Digital Services Act.00:24:50 Studio dell'Institute for the Study of War sulla guerra cognitiva condotta dalla Russia.00:30:04 Il governo britannico vara norme per contrastare l'influenza politica di stati stranieri ostili.00:31:38 L'era dello ''slopocene'': l'aumento di errori dell'AI pubblicati in documenti ufficiali.00:34:49 La polizia usa l'AI per modificare immagini di prove, compromettendone il valore legale.00:36:24 Criminale del cartello di Sinaloa usa telecamere per localizzare e uccidere informatori dell'FBI.00:39:19 Meta e Yandex hanno evaso i sistemi anti-tracciamento per seguire la navigazione degli utenti.00:42:00 Cloudflare lancia un sistema per bloccare le scansioni delle AI, restituendo controllo agli editori.00:46:39 X consentirà ai bot di scrivere Community Notes, aumentando i rischi di manipolazione.00:48:36 Ministero Giustizia inglese valuta tecnologie distopiche, come tracker sottocutanei, per monitorare criminali.00:51:27 Maxiretata USA contro lavoratori nordcoreani infiltrati in centinaia di aziende americane.00:55:22 Il Senato USA blocca la proposta di moratoria decennale sulla regolamentazione dell'AI.00:57:13 Spiegazione delle nuove copertine AI create per massimizzare le visualizzazioni e i click. ~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Your strengths aren't just what you're good at—they're your career compass. When you ignore your signature strengths, even great opportunities become draining. Discover how one IO psychologist used her strengths to break free from the "great opportunity trap" and find work that truly energizes her.   What you'll learn Why your signature strengths should guide your career experiments and decisions How to get valuable feedback from friends and family about your natural talents The difference between skills you can do versus strengths that energize you   Our book, Happen To Your Career: An Unconventional Approach To Career Change and Meaningful Work, is now available on audiobook! Visit  happentoyourcareer.com/audible to order it now! Visit happentoyourcareer.com/book for more information or buy the print or ebook here! Want to chat with our team about your unique situation? Schedule a conversation   Free Resources What career fits you? Join our free 8 Day Mini Course to figure it out! Career Change Guide - Learn how high-performers discover their ideal career and find meaningful, well-paid work without starting over.   Related Episodes Discover Your Strengths to Find Your Ideal Career (Spotify / Apple Podcasts) Should I Quit My Job? How to Know It's Time (Spotify / Apple Podcasts)

Hon är Italiens första kvinnliga premiärminister, en fantasyälskande populist som har ifrågasatts för sina kopplingar till landets mörka historia. Nya avsnitt från P3 ID hittar du först i Sveriges Radio Play. ”Io sono Giorgia, sono una donna, sono una madre!” – ”Jag är Giorgia, jag är kvinna, jag är mamma, jag är italienare, jag är kristen. Det kan de aldrig ta ifrån mig!”Orden ekar ut över en enorm folkmassa på Piazza San Giovanni i Rom hösten 2019. Vid talarpodiet står en kort kvinna med blont hår, ledigt klädd i mörka byxor och en fladdrig ljusgrå blus.Trots att hon är flankerad av flera politiska tungviktare så är det Giorgia Meloni, partiledare för Italiens bröder, som stjäl showen den här dagen. Hennes eldiga ord blir det politiska manifest som kommer att bära Meloni och hennes parti till valseger några år senare.Giorgia Melonis politiska resa inleds i början på 90-talet, när hon som 15-åring ringer på dörren till Fronte della Gioventù, det politiska partiet Movimento Sociale Italianos ungdomsförbund.Det är ett parti som grundades av den fascistiske diktatorn Benito Mussolinis anhängare, och som vid den tiden befinner sig på utkanten av det italienska etablissemanget på grund av de historiska banden till en tid som präglades av skräck och våld.P3 ID om Giorgia Meloni följer hennes utveckling från blyg tonåring med en gnagande känsla av att något är fel i det italienska samhället, till retorisk pitbull som inte räds någon motståndare på den politiska arenan.I avsnittet medverkar Eskil Fagerström, journalist på Sydsvenskan och författare till flera böcker om det moderna Italien, Giulia Kappelin Cingolani, journalist baserad i Italien, och Filip Jacobson, utrikesreporter på TV4.Klippen i avsnittet är hämtade från Rai, Right Side Broadcasting Network, Giorgia Melonis Facebooksida, Fratelli d'Italias Youtubekanal, Wine News, Diario AS, VOA Africa, Vista Agenzia Televisiva Nazionale, Vita husets Youtubekanal, British Pathé, La7 Attualità.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio ascend to the other spaceship and look for a missing Dark Lord. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: GURPS Wars S1 Ep 68: Bespoke Spokes Music Used: “Cabin Fever!” by Drozerix is licensed as … Continue reading "GURPS Wars S1 Ep 68: Bespoke Spokes"

Cosa succederebbe se domani arrivasse in Italia 1 MILIARDO di immigrati super istruiti a soli 2 euro al giorno?La possibilità concreta è già qui: miliardi di agenti digitali low-cost pronti a sostituire task ripetitivi e processi aziendali. Entro 2-3 anni interi settori rischiano enormi trasformazioni, dall'amministrazione al marketing, dal customer care alla produzione standardizzata.Il tuo lavoro potrebbe essere tra i primi a sparire o quello che beneficia maggiormente di questa rivoluzione digitale.Quanto è sicura la tua professione oggi e come potresti usare questi agenti digitali per moltiplicare il tuo business?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Benvenuti a “AmbienteOnAir” il podcast che dà voce alle novità e ai progetti che affrontano le sfide ambientali. Io sono Alessandra Casali e oggi vi porto in Umbria, lungo il corso del fiume Tevere, per scoprire una storia curiosa e scientifica allo stesso tempo. Parleremo di molluschi bivalvi, di specie aliene e di scienza partecipata. E lo faremo seguendo le tracce di una protagonista ….aliena: la Cozza zebrata

- Premere il tasto PLAY per ascoltare la catechesi del giorno -+ Dal Vangelo secondo Matteo +In quel tempo, Gesù, vide un uomo, chiamato Matteo, seduto al banco delle imposte, e gli disse: «Seguimi». Ed egli si alzò e lo seguì.Mentre sedeva a tavola nella casa, sopraggiunsero molti pubblicani e peccatori e se ne stavano a tavola con Gesù e con i suoi discepoli. Vedendo ciò, i farisei dicevano ai suoi discepoli: «Come mai il vostro maestro mangia insieme ai pubblicani e ai peccatori?».Udito questo, disse: «Non sono i sani che hanno bisogno del medico, ma i malati. Andate a imparare che cosa vuol dire: “Misericordia io voglio e non sacrifici”. Io non sono venuto infatti a chiamare i giusti, ma i peccatori».Parola del Signore.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Ari Wes, Partner at Peninsula Plastic Surgery and CEO and Cofounder of Orchid Surgical, about clinical surgery video production. Chapters 00:00 Intro 01:46 Interview Preview 02:16 No Chest-Open Heart Transplant 05:07 NSCLC Time to Surgery 07:55 Impact of Preop Invasive Nodal Staging 11:04 Air Space Spread Impacts Adenocarcinoma 14:26 Intrapericard Pneum w Broncho & Flap 16:42 Ross Procedure Unveiled 21:16 Radial Artery Harvesting Podcast 23:32 Dr. Wes Interview, Video Production 46:06 Cardiac Surgical Arrest Series 46:52 Closing They discuss the value of starting with the right camera, the impact of field of view, head-mounted cameras vs. stationary cameras, and the importance of capturing the surgeon's perspective. Additionally, they explore the educational benefits of recording surgeries, the criteria for selecting an ideal storage solution for recordings, and the future of clinical surgery videos.   Joel also highlights recent JANS articles on first fully robotic heart transplant in the US performed without opening the patient's chest, defining the optimal diagnosis-to-resection interval to reduce mortality in early-stage non-small cell lung cancer, concurrent spread through air spaces in dominant tumors impacts prognosis in synchronous multiple primary lung adenocarcinoma, and the impact of preoperative invasive nodal staging on unexpected mediastinal upstaging in early-stage non-small cell lung cancer.  In addition, Joel explores a robot-assisted intrapericardial pneumonectomy with bronchoplasty and thymic flap post neoadjuvant chemo/IO, insights into various techniques and modifications for the Ross procedure, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Faisal Bakaeen from the Cleveland Clinic on radial artery harvesting. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) First Fully Robotic Heart Transplant in the US Performed Without Opening Patient's Chest  2.) Time to Surgery in Early-Stage Non-Small Cell Lung Cancer: Defining the Optimal Diagnosis-to-Resection Interval to Reduce Mortality  3.) Concurrent Spread Through Air Spaces in Dominant Tumors Impacts Prognosis in Synchronous Multiple Primary Lung Adenocarcinoma   4.) The Impact of Preoperative Invasive Nodal Staging on Unexpected Mediastinal Upstaging in Early-Stage Non-small Cell Lung Cancer   CTSNET Content Mentioned  1.) Robot-Assisted Intrapericardial Pneumonectomy With Bronchoplasty and Thymic Flap Post Neoadjuvant Chemo/IO  2.) The Ross Procedure Unveiled: Insights into Various Techniques and Modifications   3.) The Atrium: Radial Artery Harvesting   Other Items Mentioned  1.) Cardiac Surgical Arrest—An International Conversation, Part 2  2.) Career Center   3.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio continue to explore, but are forced to deal with problems previously locked away. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: GURPS Wars S1 Ep 67: Womp Rat in Corner Pocket Music Used: “Cabin Fever!” by … Continue reading "GURPS Wars S1 Ep 67: Womp Rat in Corner Pocket"

Federica Falzea ha 43 anni, vive a Milano ma è nata e cresciuta a Lecce in una famiglia dove l'istruzione è sempre stata il vero motore di riscatto sociale. Figlia di due medici, Federica sceglie un approccio più olistico alla cura: va a studiare osteopatia a Milano, trovando alloggio presso una congregazione di suore, dove per la prima volta entra in contatto con la vita religiosa. Dopo quattro anni di studio, la svolta. Decide di lasciare la scuola per entrare in convento, dove trascorre nove anni studiando Psicologia Giovanile e Teologia. Col tempo, però, la spinta iniziale inizia ad affievolirsi e Federica decide di lasciare la vita religiosa per riprendere gli studi di osteopatia. In tre anni conclude la scuola, apre uno studio, si sposa e ha due figli.Tutto procede bene fino al 2022, quando le viene diagnosticato un tumore al peritoneo. Durante l'intervento le vengono asportati anche utero e ovaie e, dopo l'operazione, cominciano sintomi molto potenti: confusione, sbalzi d'umore, sudorazione e insonnia, inizialmente attribuiti all'intervento.Nella casa di cura dove è stata operata, nessuno la informa che la rimozione degli organi riproduttivi avrebbe causato una menopausa chirurgica precoce. Solo in seguito, grazie alla sua ginecologa, arriva la diagnosi corretta e l'inizio della terapia ormonale sostitutiva, la TOS. Federica sta meglio, ma si ritrova ad affrontare un nuovo ostacolo: i costi.La terapia, infatti, è tutta a carico suo. Tra farmaci, pomate specifiche e fisioterapia riabilitativa legata ai sintomi della menopausa, la spesa arriva facilmente a superare i 3.000 euro all'anno. Una cifra significativa, soprattutto se si considera che molte di queste cure non sono un “di più”, ma un'esigenza per continuare a vivere bene. I costi della menopausa non si fermano però alle terapie: si riflettono anche sul lavoro. Le donne affrontano questo passaggio fisiologico nel momento di massima responsabilità e rendimento professionale. Secondo uno studio anglosassone, ogni anno le donne in menopausa si assentano dal lavoro per una media di 24 ore, causando una perdita economica stimata in 15 milioni di euro. E se lavori in proprio, come Federica, il prezzo si misura in termini di mancato guadagno: «Io, da agosto del 2022, dopo circa cinque mesi, ho ripreso a lavorare. Cinque mesi senza alcuna entrata, senza alcun guadagno».Così, per contrastare anni di invisibilità e disinformazione, Federica e un'amica, Silvia, decidono di dare vita a MenoP: un progetto che vuole rompere il tabù attorno alla menopausa e dare finalmente voce a un'esperienza femminile ancora troppo spesso ignorata. Insieme organizzano focus group e incontri nelle aziende, portando formazione e consapevolezza dove ancora mancano strumenti e parole: «Cerchiamo di offrire una narrazione della menopausa diversa da quella che ci viene solitamente proposta, una narrazione in cui possiamo davvero riconoscerci e sentirci coinvolte».

Radio International - The Ultimate Eurovision Experience is broadcast from Malta's Radio 105FM on Tuesday evenings from 2100 - 0059 hours CET. The show is broadcast live on Wednesday evenings from 1900 - 2300 hours CET on the Eurovision Radio International Mixcloud Channel as well as on the Facebook Page of Eurovision Radio International with an interactive chatroom.             AT A GLANCE - ON THE SHOW THIS WEEK  Interview with Marc of Peter, Sue and Marc (Switzerland 1971, 1976, 1979 and 1981) done at the OGAE Germany Convention 2025 Interview with Dario Bezzina feat Zeppi l-Muni (Malta Eurovision Song Contest 2025) Interview with KEiiNO (Norway 2019) done at MancHagen 2025 Eurovision Spotlight: Eurovision's Magic Numbers (Vol 2) with Chris Poppe Eurovision News with Nick van Lith from www.escXtra.com Eurovision Birthday File with David Mann Eurovision Cover Spot with David Mann Eurovision Calendar with Javier Leal National Final Update for Junior and Eurovision Song Contest with Alain Forrotti  New Music Releases by Eurovision Artists  Your music requests   Peter, Sue and Marc (Switzerland 1971, 1976, 1979 and 1981) Marc Dietrich with JP and Marc (Jan 2025) Interview with Marc of Peter, Sue and Marc (Switzerland 1981): In January 2025, OGAE Germany had their annual conventon and one of the surprise guests was Marc Dietrich being one thrid of the Swiss group Peter, Sue and Marc who represented Switzerland four times at the Eurovision Song Contest. Their first participation was in 1971 with the song "Les illusion de nos vingt ans" placing Switzerland at Number 12. Then they returned five years later to the Eurovision Song Contest 1976 performing the song "Djambo, Djambo" bettering their results by reaching Number 4. Three years later, in 1979 they tried it again with the help Pfuri, Gorps and Kniri in "Troedler und Co" coming 10th and their final participation was in 1981 with their best results of their four participations reaching Number 4 with "Io senza te".  Radio International's Marc and JP had the pleasure of an interview with Marc Dietrich about their particpations in Eurovision and their career. This interview will be broadcast on the show this week. You will certainly enjoy it.    KEiiNO (Norway 2019) at MancHagen 2025 Interview with KEiiNO (Norway 2019):  Our final interview Radio International has left to broadcast from the recent edition of MancHagen Eurovision 2025 PreParty is an interview that Radio International's  Salman did with KEiiNO to catch up with the sympathetic group from Norway that became the fans' favourite in 2019 when they reached 6th place with "Spirit in the sky" in Tel Aviv, Israel. Since then, KEiiNO have gone from strength to strength and toured the Eurovision World extensively as well as releasing new material and also competing again in the Norsk Meldodi Grand Prix which is Norway's national final to the Eurovision Song Contest. Salman caught up with the trio and sent in an interview which Radio International is sharing with the fans this week.    Dario Bezzina feat Zeppi l-Muni (Malta Eurovision Song Contest 2025)     Interview with Dario Bezzina feat Zeppi l-Muni (Malta Eurovision Song Contest 2025): On Sat. 08 Feb 2025 Miriana Conte and her song "Kant" (now "Serving") was selected by the jury and Maltese public to represent Malta at the Eurovision Song Contetest 2025 in Basel in May. Miriana successfully placed Malta in the Grand Final of the Eurovision Song Contest ranking 17th at the end of the voting sequence. Earlier on in February 2025, Radio International conducted interviews with all the contestants at the Malta Eurovision Song Contest 2025 and more. This week, Radio International will broadcast an interview with Dario Bezzina feat Zeppi l-Muni who successfully qualified for the Grand Final of the Malta Eurovision Song Contest 2025 out of Semi Final 2 and then placed 9th with the song "Għażliet" You can watch all the interviews Radio International did at the Malta Eurovision Song Contest 2025  by visiting the Radio International YouTube Channel - or check out our complete coverage of the Malta Eurovision Song Contest - click here.   The Eurovision Spotlight: The Eurovision Song Contest 2025 - Eurovision's Magic Numbers:  With the summer solstice marking the start of the Summer 2025 the Eurovision Spotlight Team Members decided to continue where we left off last year at the end of summer with Eurovision's Magic Numbers. Enjoy this unique way of featuring the songs of the Eurovision Song Contest on the show. Chris Poppe will be continuing the series this week.  Eurovision News, New Song Releases, Birthday File, Coverspot, Eurovision Calendar: Also JP will be joined by David Mann for the Eurovision Birthday File and Eurovision Coverspot.  Nick will be presenting the Eurovision News courtesy of escXtra.com. There will be a lot of the great new releases of Eurovision artists on the show as well as great Eurovision Classics. Javier will be updating us on the upcoming Eurovision events in the Eurovision Calendar and Alain Forrotti gives us already some updates of the National Finals regarding the Junior Eurovision Song Contest 2025 and the Eurovision Song Contest 2026 and and....   For full details of this week's Show Content and Play List - click here

(00:00:00) "Festeggiamo i 10 anni di Apple Music" (00:00:12) Ciao Paolo Bitta (00:00:38) In attesa delle vere novità di Samsung e Google (00:02:14) Sviluppi in Casa Apple (00:03:06) I rumors su Apple (00:03:45) Arriva il MacBook con l'A18 Pro? (00:05:17) Dieci anni di Apple Music (00:07:19) Apple Music vs Spotify (00:08:49) Apple Music: Integrazione e Funzionalità (00:13:25) La storia della Musica (00:15:41) Esperienze personali con Apple Music (00:19:52) Apple Music e l'ecosistema (00:23:46) Vent'anni di Apple Podcast (00:26:41) L'evoluzione dei Podcast (00:29:33) Apple TV+ (00:34:11) Apple Fitness + (00:36:40) Dov'è Apple News? Oggi celebriamo due compleanni importanti: i 10 anni di Apple Music e i 20 anni di Apple Podcast. Un episodio nostalgico e riflessivo sui servizi Apple, dall'eredità di iTunes Store all'evoluzione dello streaming musicale, dall'integrazione ecosistemica alle chicche come iTunes Match e Replay.Con voi ripercorro la mia esperienza personale con Apple Music dal day one, analizzo l'evoluzione dei podcast da nicchia tech a fenomeno mainstream, e faccio il punto sugli altri servizi di Cupertino: Apple TV+, Arcade, Fitness+ e il sogno (ancora irrealizzato) di Apple News+ in Italia.La puntata di IO&TEch in cui ho parlato del potenziale Apple RingLa puntata del SaggioPodcast in cui sono stato ospitesVisita Digiteee e scopri tutte le notizie sulla tecnologiaSegui Digiteee su TikTokDimmi la tua su Twitter, su Threads, su Telegram, su Mastodon, su BlueSky o su Instagram.Mail jacoporeale@yahoo.it Scopri dove ascoltare il podcast e lascia una recensione su Apple Podcast o Spotify.Ascolta An iPad guy su YouTube Podcast.Supporta il podcast

Help MuggleCast grow! Become a MuggleCast Member and get great benefits like Bonus MuggleCast! Patreon.com/MuggleCast  Grab official merch! MuggleCastMerch.com Pick up overstock merch from years past, including our 19th Anniversary Shirt! MuggleMillennial.Etsy.com On this week's episode, break out the scantrons and No. 2 pencils because Harry, Ron and Hermione are finally sitting their O.W.L.s. Join Andrew, Eric, Micah, Laura and Slug Club member Stacy for the stress-inducing conclusion to Harry's fifth year at Hogwarts. And if exams weren't enough, Hagrid's been sacked and Voldemort has Sirius! Welcome Slug Club member, Stacy! Chapter-by-Chapter continues with Harry Potter and the Order of the Phoenix, Chapter 31: O.W.L.s. Our Time Turner segment takes us back to Episode 468 of MuggleCast, titled “Rubeus Hagrid's Punch Out.”  Ron cannot stop talking about his big Quidditch win! Did we ever have a friend who just wouldn't shut it about a big accomplishment? Magical Moment: Ron reminds Harry of his father James After learning about Grawp, Ron raises a fantastic point: “Have we ever come off better for mixing with one of Hagrid's monster mates?” How do the O.W.L. exams reflect real-world academic pressures? Draco drops some real world knowledge: "It's not what you know, but who you know!" Why do the students have to wait until July for their scores? Shouldn't magic allow for instant results? Wingardium Leviosa, Polyjuice Potion & Patronuses! During Harry's O.W.L.s, we get several throwbacks to the first three books! Speaking of Patronuses, is Professor Tofty playing favorites? Does he offer the other students bonus points? What does the nighttime ambush of Hagrid suggest about the Ministry's tactics? Sirius Problem: Voldemort has Harry's godfather in the Department of Mysteries! What would Harry's post-exam life look like if he didn't have a Dark Lord inside of his head? The hosts share which O.W.L. they would most like to sit! Harry overhears Professor Marchbanks tell Professor Umbridge that Dumbledore “Did things with a wand I'd never seen before!” In our Lynx Line segment for the week, we ask our Patrons what kind of things do you imagine Dumbledore doing to impress the examiners? Quizzitch: Harry struggles to name all of the moons of Jupiter for his Astronomy O.W.L. WHICH of the FOLLOWING is NOT one of Jupiter's moons? Io, Metis, Europa, Ganymede, Calypso, Themisto, Pandia, and S/2003 J 2. Join in on the fun! Tilda Swinton? Peter O'Toole? James McAvoy? Michael Cera!? On this week's Bonus MuggleCast, we discuss the actors who turned down Harry Potter roles!   Learn more about your ad choices. Visit megaphone.fm/adchoices

The AI drama is full tilt!↳ Meta and OpenAI have all but declared a war on top tech talent. ↳ Google released a free AI coding tool that will likely make huge cuts into Claude's customer base. ↳ Salesforce says AI is doing their own jobs for them. And that's just the tip of the AI iceberg y'all. Don't waste hours a day trying to keep up with AI. Instead, join us on Mondays as we bring you the AI News That Matters.Newsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Thoughts on this? Join the convo.Upcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTopics Covered in This Episode:AI Talent War: Meta vs. OpenAIAI Firms and Copyright Lawsuits UpdateOpenAI Trademark Battle with IOEleven Labs' New Voice AI LaunchUS Senate AI Regulation DealAnthropic's Claude Platform Features UpdateSalesforce's AI Workload IntegrationGoogle Gemini CLI Free Coding ToolMeta's Aggressive AI Talent RecruitmentOpenAI's Strategy to Retain ResearchersTimestamps:00:00 "AI News: Weekly and Daily Updates"03:12 AI Copyright Lawsuits: Early Rulings09:18 OpenAI-IO Trademark Dispute Unveiled12:23 Futile Lawsuit Against New Gadget14:21 "11 AI: Voice-Activated Task Assistant"17:37 "AI Strategy and Education Solutions"21:54 Federal AI Funding and State Regulation25:05 States Must Forego AI Regulation28:18 Anthropic Updates Claude with Artifacts31:23 Claude vs. Google Usage Limits37:17 Google Disrupts Coding with Free Tool40:17 Meta's AI Talent and Business Strategy44:20 OpenAI Responds to Meta Poaching45:49 AI Developments: LLaMA and Grok Updates49:14 OpenAI Faces Lawsuit Over IOKeywords:AI talent war, Meta, OpenAI, Federal judges ruling, California federal judges, Copyrighted books, Anthropic, Meta's legal win, Sarah Silverman, US Supreme Court, Intellectual property rights, New York Times vs OpenAI, Disney lawsuit, Universal lawsuit, Midjourney, State AI regulation, Federal funding, US Senate, Ten-year ban, Five-year ban, AI infrastructure, Federal AI funds, Sam Altman, IO hardware startup, Trademark battle, Hardware device, Eleven Labs, 11 AI, Voice assistant, Voice command execution, MCP, Salesforce, Marc Benioff, AI workload, AI agents, Anthropic Claude update, Artifacts feature, Artifact embedding, Salesforce customer service, Command line interface, Gemini CLI, Gemini 2.5 pro, Coding tools, Desktop coding agent, Meta poaching, Superintelligence lab, AI researchers, Meta's aggressive recruitment, Llama four, Llama 4.5, Microsoft, Anthropic, Google Gemini scheduled tasks, GoogleSend Everyday AI and Jordan a text message. (We can't reply back unless you leave contact info) Ready for ROI on GenAI? Go to youreverydayai.com/partner

ChatGPT Show Notes: In this energizing and insightful episode, John and Doubting Thomas wrap up their discussion on the dangers of digital distractions and the power of purposeful living. Against the laid-back backdrop of a mellow bar, the conversation dives into practical strategies for reclaiming focus, defining meaningful goals, and resisting the pull of clickbait content. Through relatable dialogue, poetic reminders, and heartfelt reflection, this finale encourages listeners to take back their time — one mindful choice at a time.

Crash DMs for Beth, Ellie, Io, Jen, & Milly. Not every empty town is abandoned, or actually empty. Follow this series on… ▶RSS: https://aaronbsmith.com/cogwheel/tag/cause-and-effect/feed/ ▶Patreon: https://www.patreon.com/cogwheelgaming ▶Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: Cause & Effect Ep 59: Mountain Town Music Used: “Pandora's Box (FB Mix)” by christofori is licensed as Public Domain and can be downloaded from … Continue reading "Cause & Effect Ep 59: Mountain Town"

Rejoignez la communauté iWeek et soutenez-nous sur patreon.com/iweek !Voici l'épisode 238 d'iWeek (la semaine Apple), le podcast avec ses chapitres !iPhone 17 Pro et iPhone 17 Pro Max : les quatre nouveautés photo-vidéo attendues.Enregistré samedi 28 juin 2025 à 11h45, enregistrement accessible en direct sur X, YouTube et LinkedIn Live. Un épisode châpitré : profitez-en !Présentation : Benjamin Vincent avec la participation de Gilles Dounès, ex-rédacteur en chef de MacPlus et co-auteur de “iPod backstage“ (Dunod).Au sommaire de cet épisode 238 : La nouvelle gamme iPhone 17 devrait être dévoilée par Apple à la rentrée et donc dans un peu plus de deux mois. A l'approche de la keynote de septembre, les rumeurs se multiplient sur les caractéristiques des nouveaux iPhone et notamment des deux modèles “Pro“ : l'iPhone 17 Pro et l'iPhone 17 Pro Max avec, cette semaine, plusieurs précisions sur les rumeurs qui concernent les quatre nouveautés majeures attendues pour la partie audio-vidéo : c'est l'info de la semaine.L'événement de la semaine ne concerne pas directement Apple, quoi que... puisqu'il s'agit d'IA et de la décision d'un tribunal de Californie après plainte contre Anthropic, l'éditeur de Claude, concurrent de chatGPT. Le tribunal a estimé que l'utilisation d'oeuvres protégées par le droit d'auteur pour entraîner l'IA d'Anthropic... relevait de l'usage équitable, autrement dit d'utilisations sans autorisation mais dans un cadre légal. Le jugement pourrait faire jurisprudence et on s'en inquiète, évidemment.Plusieurs infos au programme du JT de la semaine : l'iPhone 17 Air quasiment confirmé dans du code Apple, des détails sur son probable système de refroidissement qui serait une première sur iPhone, une référence au AirTag 2 dans iOS 18.6, des détails sur l'Apple Watch Ultra 3 avec une date de disponibilité potentielle à la rentrée et, enfin, un rappel de cinq batteries par Anker face à un risque d'incendie.Enfin, chers soutiens, nous l'enregistrons pour vous : le bonus hebdo exclusif. Cette semaine, suite du "retour sur" déjà consacré à la forme que pourrait prendre le premier produit chatGPT imaginé par Jony Ive et Sam Altman : dans le bonus, nous revenons sur le rétropédalage opéré par OpenAI à propos de l'acquisition de "IO", la startup de Jony Ive (pour 6,4 milliards de $) : toute mention du rapprochement a disparu du site d'OpenAI à cause d'une bataille judiciaire aux Etats-Unis à propos de la propriété de la marque, contestée par une autre entreprise, "iyO", avec laquelle plusieurs membres de l'équipe d'IO avaient été en contact.À mardi prochain, 1er juillet pour l'épisode 239 dont l'enregistrement sera à suivre en direct sur sur X, YouTube et LinkedIn Live à un horaire probablement plus tardif que d'habitude : nous vous le préciserons ici et sur X d'ici là.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

ぬるぽ放送局おたより投稿フォーム https://forms.gle/6tbmBzK6wbyavJG47 2025年6月パワープレイ 01. Stay Foolish 編曲：D.watt 原曲：東方紅魔郷 / おてんば恋娘 収録アルバム：TOHO BOOTLEGS 9 2025・5・5 Release https://www.iosysos.com/discographyportal.php?cdno=IO-0341 番組時間：79分20秒 出演者：夕野ヨシミ、たくや VOICEVOX:ずんだもん VOICEVOX:四国めたん ---- 2025/6/26に公開録音したものを配信いたします。 ラジオ記事はリスナーのEEチャンピオンさんが書いてくれているので楽してます。 ＜オープニング＞ ・自分の番組の名前が出てこないと終わりよ ・金八先生が始まるのかと思った ・金八先生そんなに前なの？ ・定年して、ちゃんとおわったんだ ・はじめての告知からやります ・今週のベスト10 ・たくさん人が来てた北海道ご当地キャラフェスタ ・楽曲提供のお知らせ 　「つよつよナースブロウちゃん！」 - Muse Dash 　歌唱：まるもこ 　作編曲：コバヤシユウヤ(IOSYS) 　作詞：john=hive(IOSYS) 　ギター：三浦公紀 ・ジョン…ハイヴ！ ・正解 ・作詞提供のお知らせ 　ブルーアーカイブ 青春あんさんぶる Vol.12「ヴァルキューレ」 　「パトランプハーモニー！」 　アーティスト：カンナ／キリノ／フブキ 　作詞：夕野ヨシミ(IOSYS) 　作曲：Nor ・ブルーアーカイブ 絆ダイアローグ Vol.12「ヨシミ」 　「イマハカラメル―Sweeten Up Later」 　アーティスト：ヨシミ 　作詞：夕野ヨシミ(IOSYS) 　作曲：KARUT　 ・ダブルヨシミです ・「憧れの日々」 　アーティスト：フウカ(CV:ファイルーズあい) 　作詞：john=hive(IOSYS) 　作曲：EmoCosine ・ブルアカは3曲出ました ・CD欲しい人はお早めに ・イオシス君やってるねー ・ゲーム『東方ダンマクカグラ ファンタジア・ロスト』DLC12 　「オーディエンスを沸かす程度の能力 feat.タイツォン」 　編曲：D.watt(IOSYS) 　2025/11/27配信 ・あれ、あずきバーなんだ ・ゴブリン・ノーム・ホーンの2回目は、ないんだ ・来週は2本撮りです ・「リスアニ！Vol.58『ブルーアーカイブ -Blue Archive-』キャラクター＆ミュージックガ　イド」 　いろんな方のインタビューが掲載されていますが、作詞家として夕野ヨシミのインタビューも掲載されています！ ・このままエンディングに行っちゃいそう ＜Aパート＞ ・昔のCMを引っ張ってきました ・MOCさんの声聞きたいなー ・ふつおたです ・ToHeartのリメイク版 ・ギャルゲー大好きフワモコちゃん ・農機屋さんの話 ・忙しいです ・需要に生産が追いつかない ・イオシスライス ・バケツで米を育てる ・​​籾摺りご用命はぜひ ・えんぴつ削りを魔改造 ・1年に1回しか使わないならリースすればいいのでは ・知らない人がトップになるのは… ・自動操舵は大事 ・ウッド村さんの最近の農業の話 ・やらしい話聞きたいよね ・鉄腕DASHが続くのはヨシ！ ・熱中症には気を付けようね ・TOKIO解散しちゃったね ・じぎゃくさんお誕生日おめでとうございます ・ロンドンブーツ解散しちゃったね ・ラジオは、もっと自由に ・キーワードはガールズバー ・ガールズバーは卒業？ ・最近はラウンジに行ってます ・ぬるぽはスナックなんだ ・もし、高級だとしたら ・名曲なのにマイナーな曲 ・リメイクの方はお持ち帰りで ・ダンスモーションの配布がしたい ・技術だけは蓄積されてるんだよな ・外で撮るのは恥ずかしかった ・7月は暇なので、いろいろやってみよう ＜Bパート＞ ・あいよ！ ・mikoおねえさんは、すごいあっちこっちで出演してますね ・みつをたです ・梅雨明けてないじゃないですか！やだー！ ・ガルマをなぜ出さない ・予定納税46万円 ・シャア専用ヅダ ・最終回は水着回 ・みこち「ご報告があります」 ・マチュからだった ・リアルタイムに見るのはいい ・あとはみなさん同人誌で ・来週から何を見たら ・Nintendo Switch2をやりましょう ・ランキングのコーナー ・実際に食べてみたい丼物 ・第1位　橘姉妹丼（ブルアカ） ＜エンディング＞ ・最近、美味しい海鮮丼食べました ・ウニ食べたいなー ・カンジャンケジャン食べました ・奥さんと娘と食べてきました ・父さんは引きこもり ・明日は、すってはっくん ・いつもの工場ゲームです ・ゲームのDEMO版を3つ用意してます ・今年も半分おわります ・7,8,9月は余裕、余裕 ・エンディングを持て余してる ・空っぽのエンディングです ・ファンボックス5周年です ・も、もうなんもないっす ・イオシスショップセールやります ・成人は18歳なのかい？ ・期日前投票に10回くらい行こう ・あの投票所何度も投票できるみたいですねー ・壁抜け投票バグ ・​​投票所をホットプレートで温める ・これ以上は利用契約に違反しちゃう

This week, we're cutting to the chase on the latest in AI, from legal battles to the impact on our brains.Here's what's in store:AI News: June 19-25 – A quick hit on the week's key headlines. 4/10A Call for Guests: If you want to be on the show, stand out! Learn how to pitch effectively and avoid the "AI-generated slop" pile.Midjourney's New Video Tools: Turn your still images into dynamic videos with new animation modes, motion intensity control, video extensions, and even external image support.The OpenAI vs. Google "IO" Showdown: Dive into the bombshell lawsuit surrounding OpenAI's $6.5 billion acquisition of Jony Ive's "Altman IO" and the trademark infringement battle with Google-backed "the original IO." Accusations include secret tracking, product purchases, and alleged threats from Sam Altman to force a name change.ChatGPT's App Store Dominance: ChatGPT's downloads nearly rival the combined might of TikTok, Facebook, Instagram, and X.Are LLMs Making Us Dumber? We'll tackle the MIT research linking ChatGPT use to cognitive decline. Plus, we'll discuss how readily available answers affect our critical thinking and the long-term implications for the next generation. As Balaji says, "AI doesn't do it end-to-end. It does it middle-to-middle. The new bottlenecks are prompting and verifying."

Meet the incredible Rebecca Sohn! She is originally a New Jersey girl but has had so many adventures since leaving home at age 18. She describes her father and how he fostered her creativity by building a stage in their basement for her to give dancing performances. Her dad involved the whole family in co-writing a play, which was basically improvised and was produced at two local schools. Her passion and love was ballet until age 16 when she tragically "grew out of a dancer's body" and gave up her dream of being the Prima Ballerina of the World. She remembers her high school English teacher, Ms Bartow, who nurtured her students' artistic sides. At 18 she moved to Boston and recalled seeing an Improv Touring Company Show, but didn't walk away thinking “This is what I want to do.” A few years later she moved to the Bay Area of California and was able to attend school and knew she wanted to be an actor. But the acting classes were full so she enrolled in an improv class, with the thought it would help her acting. While in SF she met Charna Halpern of the IO and was invited to Chicago and the rest was history! It was Charna who persuaded her to date Rebecca's (now) husband, Rich Sohn! To learn more you'll have to listen to the podcast. You can find out even more about Rebecca at her website www.rebeccasohn.com

Ahmad Shadid is the Founder and CEO of O.XYZ, an ecosystem with a mission to build the world's first sovereign super intelligence. As Ahmad put it, "AI must be a tool for the people, not a weapon for profit." O.XYZ is a complex ecosystem, starting with it's core – O.Super Intelligence which will help guide decisions, solve complex problems, and interact with people in the ecosystem; a toolbox with AI-powered products — tools that help you solve various problems using artificial intelligence; O.REASEARCH, O.INFRA, O.CHARITY, O.CAPITAL, and O.CHAIN as parts of the ecosystem.Previously, Ahmad was CEO of IO.net, leading the company to a $4.5 billion valuation in under a year. His leadership propelled IO.net to secure $2 million in a seed round with a $10 million fully diluted valuation in June 2023, followed by a groundbreaking $40 million Series A round at a $1 billion FDV in March 2024. This rapid growth culminated in the successful launch of the $IO coin on Binance, with a remarkable $4.5 billion FDV in June 2024.Ahmad is a visionary behind the DeAIO – an Autonomous AI Organization, the next step in the evolution of DAOs aiming to revolutionize AI governance and development. Demonstrating his commitment to innovation, he has personally invested $130M into the development of DeAIO. O.XYZ builds on Ahmad's legacy, aiming to redefine AI and showcase how decentralized technology can drive common progress and serve people.In this conversation, we discuss:- Creating the First AI CEO- O.CAPTAIN- The future of AI & Crypto - Flipping the Narrative: AI that Helps, Not Replaces- Your EGO vs AI - Security ops and code review will become increasingly important - The feeling of working for AI and not a person  - Building a company fully managed by AI - Living in Doha, Qatar- The future of AI & Crypto - An AI CEO that adapts workloads based on your energy and well-beingO.XYZWebsite: www.o.xyzX: @o_fndnTelegram: t.me/oxyz_communityAhmad ShadidX: @shadid_ioLinkedIn: Ahmad Shadid--------------------------------------------------------------------------------- This episode is brought to you by PrimeXBT. PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.    PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions. Code: CRYPTONEWS50This promotion is available for a month after activation. Click the link below:PrimeXBT x CRYPTONEWS50

- Premere il tasto PLAY per ascoltare la catechesi del giorno -+ Dal Vangelo secondo Luca +In quel tempo, Gesù disse ai farisei e agli scribi questa parabola:«Chi di voi, se ha cento pecore e ne perde una, non lascia le novantanove nel deserto e va in cerca di quella perduta, finché non la trova?Quando l'ha trovata, pieno di gioia se la carica sulle spalle, va a casa, chiama gli amici e i vicini e dice loro: "Rallegratevi con me, perché ho trovato la mia pecora, quella che si era perduta".Io vi dico: così vi sarà gioia nel cielo per un solo peccatore che si converte, più che per novantanove giusti i quali non hanno bisogno di conversione».Parola del Signore.

Kovi and Benjamin got together for slice at Jupiter Pizza. They loved the menu - some wood fired pizza options were the Cassiopeia, the Io, Galileo, Gaia, Mercury, Ares, and Triton. As fun as those names are, they pissed off Benjamin something royal. You see, the names are all spacey, yes, but pick a theme! We've got some planets (Ares was the Greek name fo the planet we now call Mars), random moons (from different worlds, mind you), an explorer, a constellation... It's all over the place! The eatery is called Jupiter Pizza - you'd think they'd have, at the very least, four pies named after the Galilean moons Io, Europa, Ganymede and Callisto. Nope! They didn't even refer to pepperoni as 'great red spots' - and that's just off the top of the head! Anywho, this episode was thought up in a pizzeria called Jupiter - so let's talk about places here on Earth named after places in space!

A massive repository of information about OpenAI and Altman just dropped, our take on the man who tried to marry his AI assistant, your calls, and a lot more.

Automakers, tech giants, and others push back against Trump's proposed 25% chip tariff.It's reported that the US strikes on Iran's nuclear facilities in Fordow and Natanz actually only set Iran's nuclear program back about 3-6 months. Sam Altman leaks emails between him and IYO founder Jason Rugolo ahead of their legal battle over OpenAI's IO.And we got a special funding announcement from a company creating new digital minds.Featured Guests: Rob Biederman, Managing Partner, Asymmetric Capital Partners and Dara Ladjevardian, Co-founder and CEO, DelphiDOWNLOAD PUBLIC: ⁠https://public.com/ventureInvest in everything—stocks, options, bonds, crypto. You can even earn some of the highest yields in the industry—like the 7% or higher yield you can lock in with a Bond Account. Public is a FINRA-registered, SIPC-insured platform that takes your investments as seriously as you do. Fund your account in five minutes or less at ⁠⁠(https://public.com/venture?utm_source...) and get up to $10,000 when you transfer your old portfolio.All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Public Investing, Inc., member FINRA & SIPC. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank. Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1890144), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. A Bond Account is a self-directed brokerage account with Public Investing, member FINRA/SIPC. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The 7%+ yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees, as of 5/15/2025. A bond's yield is a function of its market price, which can fluctuate; therefore, a bond's YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our Fee Schedule (https://public.com/disclosures/fee-sc...)*Terms and Conditions (https://help.public.com/en/articles/6...) apply.

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Jason Howell and Jeff Jarvis break down 1) Anthropic's fair use win in the AI copyright case 2) Pirated book datasets and the looming shadow library trial 3) Apple's rumored talks to acquire or partner with Perplexity 4) What a Perplexity deal could mean for Siri and search 5) Meta's own interest in Perplexity and AI talent wars 6) Google's new Chromebook Plus and on-device AI upgrades 7) Meta's AI-powered smart glasses and the rise of wearables 8) UK study on kids' generative AI habits 9) Chatbots filling therapy gaps for children 10) Sam Altman's take on raising kids with AI 11) OpenAI's IO trademark dispute with Jony Ive 12) Meta's struggle to label AI-generated video 13) Senate's move to block state AI laws 14) Perplexity's Comet browser for Windows 15) John Oliver's takedown of viral AI slop. Subscribe to the YouTube channel! ⁠⁠⁠⁠https://www.youtube.com/@aiinsideshow⁠⁠ Enjoying the AI Inside podcast? Please rate us ⭐⭐⭐⭐⭐ in your podcatcher of choice! Note: Time codes subject to change depending on dynamic ad insertion by the distributor. CHAPTERS: 0:01:03 - Anthropic Scores a Landmark AI Copyright Win—but Will Face Trial Over Piracy Claims 0:25:35 - Bill Gross' ProRata.ai launches its "ethical search engine," gist.ai 0:28:27 - Apple is reportedly considering the acquisition of Perplexity AI 0:35:21 - Meta held talks to buy Thinking Machines, Perplexity, and Safe Superintelligence 0:38:48 - Google brings new Gemini features to Chromebooks, debuts first on-device AI 0:44:41 - Introducing Oakley Meta Glasses, a New Category of Performance AI Glasses 0:53:28 - Turing Institute study on children and AI 0:56:55 - Kids Are in Crisis. Could Chatbot Therapy Help? 1:01:50 - OpenAI CEO says his kids will ‘never be smarter than AI'— and that his parenting style relies on ChatGPT 1:04:09 - OpenAI pulls promotional materials around Jony Ive deal due to court order 1:05:51 - OpenAI's first AI device with Jony Ive won't be a wearable 1:07:10 - Meta told oversight board it can't automatically detect AI-manipulated video or audio. 1:08:13 - Senate Can Keep Ban on State AI Rules in Trump Tax Bill 1:09:51 - Perplexity's AI-powered browser opens up to select Windows users 1:10:50 - John Oliver on AI slop Learn more about your ad choices. Visit megaphone.fm/adchoices

出演者： miko、quim 配信ペース： 隔週水曜日 番組時間：86分35秒 ♯本番組はリモート収録です。 ♯収録時環境の影響により、全体的に聴き取り辛くなっております。 　申し訳ございません。 mikoラジ、第375回です。 海外（米、中）帰りの我さんと、銚子帰りのしがないさん。 それぞれの多忙な日々を、お家ラジオ感覚でざっくりお届け！ SNSにポストしていないことも、あったり無かったりな約80分。 最後までごゆるりとお楽しみくださいませ。 ♯途中で色々とノイズ等入りますが、収録時のものです。 　ご安心ください、お手持ちの機器は正常です。 //////////////////// VOICEVOX:ずんだもん VOICEVOX:四国めたん //////////////////// -------------------- ●お便り募集中！ mikoラジでは以下の内容でお便りを募集中です！ ・ふつおた 　／普通のお便り、お待ちしています！ ・mikoは大変な絵を描いていきました 　／miko画伯に描いて欲しいお題をお待ちしています！ ・メシヲコエテ 　／料理人・mikoに教えて欲しいレシピをお待ちしています！ bit.ly/2GAWjyv 投稿フォームからラジオに投稿が出来ます！ コーナー名を選び、メッセージ・ラジオネーム・お所を入力して、 どんどん送ってください！　お待ちしています！！ ------------ 本ラジオのメインパーソナリティーである「チーム我等(miko/quim)」、 それぞれ以下個人サークルにて活動中です。 ・miko：miko ・quim：SHIGANAI RECORDS（ shiganai.com/ ） 活動詳細については、上記HPの他 各人のブログ/twitter等にて随時告知しておりますので、チェックしてみてください！ ・みころぐ。(mikoのブログ)（ ameblo.jp/miko-nyu/ ） ・@ mikonyu(mikoのtwitter)（ twitter.com/mikonyu ） ・@ quim(quimのtwitter)（ twitter.com/quim ） --- その他の活動については、以下のとおりです！ -- チーム我等がメインクルーとして活動していた「アルバトロシクス（ albatrosicks.com/ ）」、 これまでリリースしたCDは、イオシスショップ（ iosys.booth.pm/ ）にて頒布しております。ご興味ある方は是非！ ---------- ☆2025年6月IOSYSはいてない.comパワープレイ楽曲 01. Stay Foolish 編曲：D.watt 原曲：東方紅魔郷 / おてんば恋娘 収録アルバム：TOHO BOOTLEGS 9 2025・5・5 Release https://www.iosysos.com/discographyportal.php?cdno=IO-0341

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $5 a month for full episodes, bonus eps and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!Apologize for the delay but we've got today's ep filled with lots of bits and lots of laughs! Ollie Hobson and Lauren Summers join us on the pod today to chat'n'prov about palm readings, triple Virgos, ham sub snacks, slip'n'slides and more!FUDGE and Friends with Erin Keif and Jessie Kendall is going down tonight at iO at 8 pm. If you plan on coming, PLZ use code FUDGEFRIEND to get your discount online!Follow Ollie on socials for info on upcoming shows and music!Follow Lauren for updates on where to see her performing around town!Performers:Hosts:⁠ ⁠Damian Anaya⁠⁠,⁠ ⁠Tim Lyons⁠⁠, and⁠ ⁠Dan White⁠⁠

Ce mardi 24 juin, Frédéric Simottel a reçu Yves Maitre, operating partner chez Jolt Capital et ancien président de HTC, Clément David, président de Theodo Cloud, et Lucas Perraudin, fondateur de AI Partners et ancien directeur de Meta Reality Labs. Ils se sont penchés sur l'appareil mystérieux d'OpenAI et de "io" de Jony Ive, et l'intention de Mark Zuckerberg de relancer sa stratégie d'IA, dans l'émission Tech & Co, la quotidienne, sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez-la en podcast.

In this episode, we welcome Alan Taylor. Alan is an Emmy-winning Director who has worked on shows including “The Sopranos,” “Six Feet Under,” “Sex in the City,” “The West Wing,” “Mad Men,” “Deadwood,” “Game of Thrones” and “House of the Dragon”. He's also directed films such as The Many Saints of Newark, Thor: The Dark World, and Terminator: Genisys. In our chat, he shares about his early days, cinematic inspirations, experiences on epic shows such as “The Sopranos,” working with James Gandolfini — plus many insights into his creative process and workflow.“The Making Of” is presented by AJA:Commercial shoots require speed and precision, which is why Dubai-based freelance editor Nikolay Ivanov depends on AJA's Io 4K Plus for fast, reliable I/O for on set editorial. Find out how he uses the technology alongside other creative tools to collaborate with stakeholders and deliver cuts while the camera is still rolling. Read the Story HereVimeo L.A. Event:Tuesday, June 24 | VidiotsA night of inspiring Vimeo Staff Picks + live filmmaker commentary!Join the Vimeo curation team as they screen recent Staff Picked films with live, unscripted commentary from some of the best creators on Vimeo.6:30pm Doors7:30-9pm Films + commentary 9-11pm Reception - complimentary drinks + bites!RSVP required. Screening and reception are free to attend!Register hereThunderbolt 5 Speed. Ultra Portable Storage.The OWC Envoy Pro Ultra the first portable SSD to harness the power of Thunderbolt 5, delivering real-world speeds over 6000MB/s in a rugged, pocket-sized design. With up to 4TB of capacity and next-gen bandwidth, it's built for high-res video, VFX, and demanding post-production workflows—anytime, anywhere. Lightweight, bus-powered, and blazing fast, it redefines what portable storage can do.Explore it hereNew Solutions from Videoguys:Now through June 30, 2025, get more value when you buy an Atomos monitor-recorder from Videoguys.com! Purchase a Ninja or Ninja Ultra and receive a FREE qualified 240GB SSD. Upgrade to a Shogun Classic, Shogun Ultra, or Sumo 19SE and get a FREE qualified 480GB SSD. To claim your free drive, simply buy from Videoguys.com and complete the mail-in rebate directly through Atomos.With five big reasons to go Atomos—record direct from the sensor, enable a direct-to-edit workflow, capture longer sessions, access pro monitoring tools, and share your shoot—this is the perfect time to upgrade. Act fast, this offer ends June 30, 2025! Call Videoguys at 800-323-2325 to find the right Atomos monitor-recorder for your workflow.Browse hereCheck out the ZEISS Otus ML:Now on sale, the Otus ML 1.4/50mm photography lens from ZEISS is the new generation of high-quality optics for your photographic art. Find it at your favorite photo retailer! Explore it herePodcast Rewind:June 2025 - Ep. 87…“The Making Of” is created by Michael Valinsky.Promote your products or services to over 200,000 filmmakers, TV production pros, and content creators reading this newsletter… contact us at mvalinsky@me.com Get full access to The Making Of at themakingof.substack.com/subscribe

Stai imparando l'italiano e vuoi che il tuo modo di parlare sembri davvero naturale? Allora devi assolutamente evitare quegli errori comuni che tradiscono immediatamente uno straniero. In questo articolo scoprirai i 10 errori più frequenti (+1 bonus) che impediscono a molti stranieri di parlare come dei veri italiani. Una volta che avrai imparato a riconoscerli ed evitarli, il tuo italiano apparirà molto più fluente e autentico! 10 Errori da Evitare per Suonare come i Madrelingua A proposito di errori, in questo articolo ne troverai 10 da evitare per non far arrabbiare una mamma italiana. 1. L'Uso Scorretto di "Bello" e "Quello" Prima dei Sostantivi Uno degli errori più comuni riguarda l'uso di "bello" e "quello" davanti ai sostantivi. Molti studenti dicono erroneamente: ❌ SBAGLIATO: Belli amici Quelli libri ✅ CORRETTO: Begli amici Quei libri La regola fondamentale: "bello" e "quello" usati prima di un sostantivo o un aggettivo funzionano esattamente come gli articoli determinativi. Quindi diremo: Bell'amico (come "l'amico") Begli amici (come "gli amici") Quel libro (come "il libro") Quei libri (come "i libri") Quell'albero (come "l'albero") Quegli alberi (come "gli alberi") Ricorda: "belli" e "quelli" non vanno MAI usati prima di un sostantivo! Sono forme che si usano solo quando l'aggettivo è separato dal nome. 2. Milioni e Miliardi: Una Sola "L" e la Preposizione "Di" Un errore molto comune riguarda la scrittura di "milioni" e "miliardi". Attenzione: in italiano hanno una sola "L"! ✅ CORRETTO: Un milione di euro Un miliardo di persone Regola importante: Dopo "milione" o "miliardo" non dimenticare mai la preposizione "DI"! Eccezioni da ricordare: Se dopo "milione" (o "miliardo") c'è un'altra quantità, non si usa più la preposizione: "Un milione e 520mila persone" La preposizione "DI" ritorna con "e mezzo": "Un milione e mezzo di persone", "Un milione e mezzo di euro" 3. Verbi che Richiedono l'Ausiliare "Essere" Molti studenti pensano che solo i verbi di movimento o i verbi di cambiamento di stato richiedano l'ausiliare "essere" nei tempi composti. Ma attenzione! Ci sono altri verbi importanti che utilizzano "essere": Piacere: "Quel libro non mi è piaciuto per niente" Costare: "Questa casa è costata molto" / "Questo viaggio è costato molto" Durare: "Il film è durato troppo" Mancare: "Voi mi siete mancati" Questi verbi sono spesso dimenticati dagli studenti stranieri, ma sono fondamentali per parlare correttamente l'italiano! 4. Ripetizione: Imperfetto vs Passato Prossimo Molti studenti si confondono quando devono esprimere una ripetizione nel passato. La domanda è: quando usare l'imperfetto e quando il passato prossimo? La regola è semplice ma cruciale: IMPERFETTO = ripetizione non determinata nel numero PASSATO PROSSIMO = ripetizione con un numero determinato Esempi pratici: "Da bambina mangiavo spesso i biscotti" (non sappiamo quante volte) "Da bambina ho mangiato 10 volte i biscotti" (numero preciso) "Ve l'ho ripetuto mille volte!" (numero determinato, anche se esagerato) 5. Andare vs Venire: La Differenza che Fa la Differenza Uno degli errori più difficili da correggere riguarda l'uso di "andare" e "venire". La differenza è fondamentale per suonare naturali: ANDARE = indica allontanamento rispetto a chi parla (o chi ascolta) VENIRE = indica avvicinamento verso chi parla (o chi ascolta) Esempi chiarificatori: "Tu vai a Parigi" (io non sono a Parigi) "Tu vieni a Parigi" (io sono a Parigi) "Io vado a Parigi" (chi ascolta non è a Parigi) "Io vengo a Parigi" (chi ascolta è a Parigi) Caso speciale importante: VENIRE si usa anche quando chi parla e chi ascolta si muovono INSIEME verso la stessa destinazione, anche se nessuno dei due è lì. Esempio: "Stasera vado al cinema." "Vengo anche io!" (con te,

Meet the talented Rich Sohn! After being introduced to improv in college, he moved to Chicago in 1987, so he's definitely a seasoned pro in the Improv world. He studied, taught and directed at the Annoyance Theatre, IO and, Second City. As a teacher, he was at The Annoyance Theatre where Rich primarily found his voice and approach. His teaching style is highly influenced by Mick Napier. He moved to LA in 2017 and now teaches at The Pack Theater. He has directed, written and performed hours and hours of comedy content. Designed curriculum to help professionals and students find and perfect their voice. And improvisation has remained at the root of everything he does. We talked about what he looks for in his students and his teaching style. I think you'll admire Rich as much as I do!

“You don't have to transition your entire business. You just need to start. Small beginnings are okay.”  Revolutionizing Water Treatment Through Smart Tech  In this episode of Scaling UP! H2O, host Trace Blackmore welcomes Kevin Kuhne, Founder and President of Energy Resource Products, LLC, for a deep-dive conversation on the emerging role of smart technology and artificial intelligence in water treatment.  With decades of experience leading tech-driven innovation, Kevin unpacks how intelligent systems, edge computing, and real-time data processing are reshaping operations in the field—from cooling towers to complex distribution networks.  Whether you're managing plant performance or driving strategic growth, this episode offers a credible look into the future of industrial water management.   From Controllers to Edge-Based Intelligence  Kevin introduces the evolution of traditional controllers into what he calls “computers at the edge.” These intelligent systems collect real-time data, deliver predictive alerts, and can execute secure firmware updates—all without requiring field visits. This shift eliminates the dependency on gateways and streamlines site management through centralized dashboards, saving time and resources.  He illustrates how these systems not only detect pump failures before they occur but also reduce chemical overdosing incidents by offering immediate visibility into feeder issues and sensor discrepancies.   Breaking the Barrier: Selling Smart Tech to Stakeholders  One of the recurring challenges in adopting new technology is overcoming skepticism—especially from IT teams and procurement stakeholders. Kevin outlines strategies for simplifying the sales conversation: focus on specific ROI outcomes like labor savings, chemical usage reduction, and improved equipment uptime. He also breaks down how modern security protocols and machine-to-machine communication are easing concerns around connectivity and data protection.   AI and the Cloud: Turning Data into Action  The discussion advances into how AI-enabled platforms now process disparate data streams in the cloud to support smarter decision-making. Rather than waiting for weekly reports, professionals can now access dynamic dashboards and build customized data visualizations to proactively manage client sites from any location.  Kevin emphasizes that this shift empowers service professionals, not replaces them. By removing manual data bottlenecks, smart tech allows for more impactful engagement and long-term client retention.  Future-Proofing the Industry  Kevin predicts a near future where IO configurations fade, sensors become brand-agnostic, and user interfaces resemble common mobile apps. He encourages water professionals to begin small—pilot smart technology in a single location, gather feedback, and use those wins to accelerate broader adoption.  He closes with a message for early-career professionals: embracing smart technology from the start will enable them to deliver higher value and grow their impact in the industry.   Conclusion  As industries move toward intelligent infrastructure, water professionals must adapt. This episode provides a grounded, expert-led perspective on how to practically and securely implement these technologies. For technical managers, engineers, and company leaders, this is a timely and strategic conversation you won't want to miss.  Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps    01:38 – Trace Blackmore shares a reflection on sharks and ecosystem sustainability, tying into the episode's broader theme of technology and responsible action.   10:06 – Water You Know with James McDonald  11:30 – Upcoming Events for Water Treatment Professionals   14:08 – Interview with Founder, President, and Coach Kevin Kuhne of Energy Resource Products  16:11 - Kevin defines smart tech, contrasting traditional controllers with edge-based computing that delivers real-time data, predictive analysis, and remote access  33:10 — Future technology trends 36:12 — Message for newcomers: Kevin encourages young professionals to embrace tech as a tool for empowerment, not a threat    Quotes  “Your customer is already integrating AI in other parts of their business. If we're not doing it, someone else will.”   “Security is the real roadblock, but if the equipment has a computer-type base of operation, IT is far more comfortable.”  “Smart tech is identifying those areas that we can enhance information, translate it, and then act on it.”    Connect with Kevin Kuhne  Phone: 17632263945  Email: kevin@energyresourceproducts.com   Website: www.energyresourceproducts.com    LinkedIn: www.linkedin.com/in/kevin-kuhne-1812626   Click HERE to Download Episode's Discussion Guide    Guest Resources Mentioned   12 Rules for Life: An Antidote to Chaos: Jordan B. Peterson   The Problem of Pain by C.S. Lewis  A Christmas Carol (Collins Classics) by Charles Dickens    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind  AWT Technical Training (Coming Soon - 2026)   422 Inside the Association of Water Technologies with John Caloritis    Water You Know with James McDonald   Question: What is the breakpoint chlorination ratio of chlorine to ammonia required to reach a true free chlorine residual?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

Apple's WWDC and Google I/O have both come and gone, and... well, we took a look at I/O and it was practically all AI this year, so we skipped that. But Apple's annual developer's conference was surprisingly light on AI features -- in fact, the continuing absence of the AI-driven Siri and other features announced last year is itself a notable story -- so this week we recapped what Apple brought to WWDC instead, including its first major UI refresh in a decade, interesting additions to smaller stuff like Wallet and Shortcuts, the ever-more-laptop-like nature of the iPad, the end of x86 support and beginning of annual versioning for MacOS, and a bunch of other stuff. Support the Pod! Contribute to the Tech Pod Patreon and get access to our booming Discord, a monthly bonus episode, your name in the credits, and other great benefits! You can support the show at: https://patreon.com/techpod

We spent the week learning keybindings, installing dependencies, and cramming for bonus points. Today, we score up and see how we did in the TUI Challenge.Sponsored By:Tailscale: Tailscale is a programmable networking software that is private and secure by default - get it free on up to 100 devices! 1Password Extended Access Management: 1Password Extended Access Management is a device trust solution for companies with Okta, and they ensure that if a device isn't trusted and secure, it can't log into your cloud apps. Unraid: A powerful, easy operating system for servers and storage. Maximize your hardware with unmatched flexibility. Support LINUX UnpluggedLinks: